PDCD1LG2 and cancer: By applying the conventional threshold for tumor PD-L1-positivity of ≥1% in cancer cells or stromal immune cells, we found that all nine TNBC tumors were PD-L1-positive, with eight (88.9%) of these also being PD-L2-positive.